AIRLINK 72.59 Increased By ▲ 3.39 (4.9%)
BOP 4.99 Increased By ▲ 0.09 (1.84%)
CNERGY 4.29 Increased By ▲ 0.03 (0.7%)
DFML 31.71 Increased By ▲ 0.46 (1.47%)
DGKC 80.90 Increased By ▲ 3.65 (4.72%)
FCCL 21.42 Increased By ▲ 1.42 (7.1%)
FFBL 35.19 Increased By ▲ 0.19 (0.54%)
FFL 9.33 Increased By ▲ 0.21 (2.3%)
GGL 9.82 Increased By ▲ 0.02 (0.2%)
HBL 112.40 Decreased By ▼ -0.36 (-0.32%)
HUBC 136.50 Increased By ▲ 3.46 (2.6%)
HUMNL 7.14 Increased By ▲ 0.19 (2.73%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.67 Increased By ▲ 1.07 (2.92%)
OGDC 137.75 Increased By ▲ 4.88 (3.67%)
PAEL 23.41 Increased By ▲ 0.77 (3.4%)
PIAA 24.55 Increased By ▲ 0.35 (1.45%)
PIBTL 6.63 Increased By ▲ 0.17 (2.63%)
PPL 125.05 Increased By ▲ 8.75 (7.52%)
PRL 26.99 Increased By ▲ 1.09 (4.21%)
PTC 13.32 Increased By ▲ 0.24 (1.83%)
SEARL 52.70 Increased By ▲ 0.70 (1.35%)
SNGP 70.80 Increased By ▲ 3.20 (4.73%)
SSGC 10.54 No Change ▼ 0.00 (0%)
TELE 8.33 Increased By ▲ 0.05 (0.6%)
TPLP 10.95 Increased By ▲ 0.15 (1.39%)
TRG 60.60 Increased By ▲ 1.31 (2.21%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,566 Increased By 157.7 (2.13%)
BR30 24,786 Increased By 749.4 (3.12%)
KSE100 71,902 Increased By 1235.2 (1.75%)
KSE30 23,595 Increased By 371 (1.6%)
Editorials

Researchers create new type of gene-editing technology to fight diseases

In order fight diseases more effectively, Chinese researchers claim to have developed a totally new type of gene-ed
Published July 20, 2019 Updated July 23, 2019

In order fight diseases more effectively, Chinese researchers claim to have developed a totally new type of gene-editing technology that will serve as a better alternative to the CRISPR one.

Researchers from China’s Peking University have created a new gene-editing technology dubbed ‘LEAPER’. They believe that the new technology shows a more promising result as an alternative to CRISPR gene-editing tech for fighting human diseases.

LEAPER, which stands for ‘leveraging endogenous ADAR for programmable editing of RNA’, works in a similar fashion to the CRISPR-Cas13 that targets RNA molecules as opposed to the DNA ones like it’s done in CRISPR-Cas9, explained Futurism.

Scientists close to HIV cure in humans after treating mice through gene-editing

The CRISPR-Cas13 is dependent on both a guide RNA and the Cas13 enzyme in order to make the edits to its RNA. The LEAPER, in comparison, requires just one component called ‘arRNA’, which in turn makes the system ‘more easily deliverable and less likely to result in unwanted cellular immune responses’, the team told Chinese new outlet Caixin.

Since the technology does not change the DNA directly and rather makes use of native proteins, it is unlikely to cause any heritable changes, while also being precise and safe at the same time, researcher Zhou Zhuo told The Global Times.

In the tests of cells taken from people with the genetic disorder Hurler syndrome, the new LEAPER system was able to correct ‘sufficient amounts’ of the cells’ mutated RNA. Zhuo said that there are obvious prospects in using this technology is disease treatment and can act as a good potential alternative.

Moreover, the research is still in its early stages, with the team now moving on to animal tests. Hence, it will take time for LEAPER to entirely replace CRISPR as the paramount gene-editing technology.

Copyright Business Recorder, 2019

Comments

Comments are closed.